Revolutionary Blood Test for Autism Risk Launches During Acceptance Month

As April brings Autism Acceptance Month to the forefront, a significant breakthrough in early autism detection is making waves. MARAbio Systems has introduced an innovative blood test aimed at identifying maternal autoantibodies that are linked to a specific subtype of autism, known as Maternal Autoantibody Related Autism (MARA). This groundbreaking test is designed for mothers and boasts an impressive predictive accuracy of over 97% for diagnosing autism in their children.

This new test, named the MAR-Autism™ Test, was further refined from its initial rollout in late 2025 and now offers a robust approach to autism risk assessment. The Centers for Disease Control and Prevention (CDC) reports that autism now affects approximately one in 31 children, making the timing of this development all the more critical.

Dr. Michael Paul, President and CEO of MARAbio, emphasizes the impact of this test: “This Autism Acceptance Month, we are thrilled to provide the first-ever blood test to identify specific maternal autoantibodies for a subtype of autism. The importance of having a reliable, biology-based prediction of autism prior to pregnancy cannot be overstated.”

Understanding the MAR-Autism Test

The MAR-Autism Test is unique in that it is performed on the mother, identifying specific patterns of autoantibodies that have been scientifically linked to alterations in fetal brain development. Mothers can take this simple blood test either before or after pregnancy, allowing for meaningful insight into potential autism risk for future children. This is especially vital for families with a history of autism or developmental delays where informed family planning is paramount.

Unlike traditional evaluations, which generally rely on assessing behavior in children, the MAR-Autism Test focuses solely on the maternal blood sample, which not only simplifies the testing process but also ensures a higher specificity and lower false positive rate. The test has shown a specificity rate of 99.8%, equivalent to a mere fraction of false positives, which enhances confidence in its outcomes.

Dr. Judy Van de Water, an expert in immunology and the founder of MARAbio, played a pivotal role in the underlying research supporting the test. She notes that previously unanswered questions surrounding autism's etiologies are now grounded in scientific evidence, providing relief to countless families. “For many families, one of the most difficult questions has always been why. This research provides a scientifically grounded answer for a significant subset of autism cases,” she explains.

Broad Accessibility and Utilization

A significant part of MARAbio's mission is to ensure this key diagnostic tool is accessible to a wide range of families, particularly those who may face difficulties accessing specialized healthcare services. The MAR-Autism Test can now be ordered by healthcare providers throughout most of the United States, and thanks to advancements in telehealth, mothers can easily undergo virtual assessments, receive authorization, and arrange for their blood sample collection without needing to visit a clinic in person.

This innovative approach is particularly beneficial for families already navigating the complexities of autism care, who frequently encounter logistical barriers and time constraints in getting necessary assessments.

As we commemorate Autism Acceptance Month, the launch of the MAR-Autism Test represents a critical shift in understanding and managing autism. It provides families with dependable, science-based insights that can positively influence family planning, lead to earlier interventions, and support the drive towards future therapies aimed at mitigating the developmental impacts of autism.

For further information about the MAR-Autism Test, please visit www.marautism.com.